Compare 8x8 Inc (EGHT) vs Mesoblast Limited (MESO) Price & Performance

EGHT trades at $2.06, down 8.04% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with five consecutive quarters of revenue growth and consistent earnings beats, though profitability remains thin with a 0.64% net margin. Recent AI product expansions and partner program launches signal strategic growth initiatives. Analyst consensus targets $3.13, representing 52% upside potential from current levels.

EGHT presents a compelling risk-reward profile with significant analyst upside but faces execution risks in a competitive communications sector. The transition to profitability in 2026 forecasts and strong institutional support offset near-term volatility concerns. Key risks include high debt levels and margin pressure, while AI adoption growth and consistent earnings outperformance provide catalysts for valuation expansion.

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.